Skip to Content

QIAGEN N.V. (NYSE: QGEN)

Merger

  • Date:
  • 3/3/2020
  • Company Name:
  • QIAGEN N.V.
  • Stock Symbol:
  • QGEN
  • Company Name - Buyer:
  • Thermo Fisher Scientific Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 3/3/2020

Case Finder

Locate any case using the tools below.

NEW YORK, March 3, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of QIAGEN N.V. (NYSE: QGEN) breached their fiduciary duties or violated the federal securities laws in connection with the company’s proposed merger with Thermo Fisher Scientific Inc.

On March 3, 2020 QIAGEN announced that it had signed an agreement to merge with Thermo Fisher for $11.5 billion. Per the merger agreement QIAGEN stockholders will receive approximately $43.58 in cash for each share of QIAGEN common stock owned. The deal is scheduled to close in the first half of 2021.

Bragar Eagel & Squire is concerned that QIAGEN’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for QIAGEN stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in QIAGEN N.V.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: